Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Exportar:

Email
Adicionar mais destinatários

Enviar resultado
| |

EZH2 Expression in Naturally Occurring Canine Tumors.

Choi, Hyun-Ji; Lee, Han-Byul; Park, Hyun-Kyu; Cho, Sung-Min; Han, Hyo-Jeong; Lee, Sang-Joon; Lee, Ji-Young; Nam, Su-Jeong; Cho, Eun-Ho; Son, Woo-Chan.
Comp Med; 68(2): 148-155, 2019 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-29631655

Resumo

Enhancer of zeste homolog 2 (EZH2) shows upregulated expression in tumors and is an important driver of tumor development and progression. However, the mechanism underlying the mediation of tumor aggressiveness by EZH2 remains unclear. We here investigated the levels of EZH2 in various normal and tumorous dog tissues and compared these patterns with those of the corresponding human tissues. Immunohistochemical analysis showed positive staining for EZH2 in 76 of 82 cases of canine tumors, whereas low or negligible staining occurred in normal tissues and other canine tumors, including hepatocellular adenoma and lipoma. In particular, canine lymphoma, melanoma, basal cell tumors, squamous cell carcinoma, and prostate cancer all show EZH2 overexpression, as do their human counterparts. Given the similarities of spontaneous canine tumors to human cancers, we believe that these canine tumors can be used as animal models in future research and clinical trials in the development of EZH2 inhibitors.
Selo DaSilva